GCP
COGT icon

GSA Capital Partners’s Cogent Biosciences COGT Stock Holding History

GSA Capital Partners’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$288K Sell
7,444
-1,874
-20% -$65.6K 0.02% 1329
2026
Q1 		$359K Buy
9,318
+491
+6% +$18.1K 0.02% 1133
2025
Q4 		$314K Buy
+8,827
New +$248K 0.03% 1143
2025
Q2 		– Sell
-25,248
Closed -$151K – 1789
2025
Q1 		$151K Buy
+25,248
New +$198K 0.01% 1457
2024
Q1 		– Sell
-96,014
Closed -$565K – 1662
2023
Q4 		$565K Buy
96,014
+85,733
+834% +$657K 0.05% 720
2023
Q3 		$100K Buy
+10,281
New +$122K 0.01% 1388

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GSA Capital Partners's COGT Position: Q2 2026 in Review

GSA Capital Partners reduced its Cogent Biosciences (COGT) stake by 20% in Q2 2026, selling an estimated $65.6K and leaving 7,444 shares worth $288K. The position accounts for 0.02% of the portfolio, ranked #1329.

GSA Capital Partners first reported a position in COGT in Q3 2023 and has held it in 6 quarters since. The position peaked at $565K in Q4 2023. 322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • GSA Capital Partners held 7,444 shares of Cogent Biosciences worth $288K as of Q2 2026.
  • GSA Capital Partners sold 1,874 Cogent Biosciences shares in Q2 2026, an estimated $65.6K.
  • Cogent Biosciences made up 0.02% of GSA Capital Partners's portfolio in Q2 2026, its #1329 holding.
  • GSA Capital Partners first reported a position in Cogent Biosciences in Q3 2023 and has held it in 6 quarters since.
  • GSA Capital Partners's Cogent Biosciences position peaked at $565K in Q4 2023.
  • 322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.